China’s Wanbang Expands Agreement With Israel’s D-Pharm For Stroke Drug
This article was originally published in PharmAsia News
Executive Summary
China’s Wanbang Biopharmaceuticals has agreed to expand its marketing agreement with Israel’s D-Pharma for its DP-b99 drug for ischemic stroke.